Elanco Animal Health Incorporated (ELAN)
Listed on NYSE • Healthcare / Drug Manufacturers - Specialty & Generic
Overview
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Explore More Data
Key Information
Symbol:
ELAN
CEO:
Jeffrey N. Simmons
Exchange:
NYSE
CIK:
0001739104
Website:
https://www.elanco.com
SEC Filings:
View SEC →
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Price
21.6
Change
-0.9
Change %
-4.00%
Open
22.93
Previous Close
22.5
High
22.94
Low
21.38
Volume
12,801,882
Market Cap
10,731,175,936
EV/EBITDA
16.52
Capital Structure (Updated: Nov 05 04:00 PM EST)
Shares Outstanding
496,813,702
FloatShares
492,938,555
Float Ratio
99.22%
Shares Short
24,797,955
Short Percent Of Float
The percent of float shares currently sold short. Reflects market sentiment and risk of a short squeeze.
6.90%
Short Ratio
Days needed to cover all short positions. Indicates short-selling pressure.
4.5 trading days
Held Percent Insiders
1.05%
Held Percent Institutions
110.41%
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-05 |
| Earnings Call | 2025-11-05 |
| Avg EPS Estimate | 0.1366 |
| Low EPS Estimate | 0.11 |
| High EPS Estimate | 0.17 |
| Revenue | |
| Avg Revenue Forecast | 1,082,185,040 |
| Low Revenue Forecast | 1,058,000,000 |
| High Revenue Forecast | 1,096,800,000 |
ELAN Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $539,000,000 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 1.18 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 2.596 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $4,208,999,936 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
ELAN Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $842,000,000 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $572,000,000 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $1,212,375,040 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 54.73% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 6.85% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | 9.68% | Net profit margin, which reflects overall profitability. |
ELAN Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 62.12% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $4,208,999,936 | Used together with cash and EBITDA to assess debt-paying ability. |
ELAN Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 4.80% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for ELAN (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $21.6 | Latest stock trading price |
| Price Target (High) | $25 | Analyst highest expected price |
| Price Target (Low) | $17 | Analyst lowest expected price |
| Price Target (Average) | $21.55 | Average target price across analysts |
| Price Target (Median) | $23 | Median of target prices |
| Average Rating Score | 1.87 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | buy | Consensus rating |
| Analyst Coverage Count | 11 | Number of analysts providing estimates |
| Cash Holdings | $539,000,000 | Total cash held by the company |
| Cash per Share | $1.08 | Cash value per outstanding share |
| Total Debt | $4,208,999,936 | Company's total debt |
| Quick Ratio | 1.18 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 2.596 | Overall short-term liquidity |
| Debt/Equity Ratio | 62.12% | Leverage ratio: Debt / Equity |
| EBITDA | $842,000,000 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $4,483,999,744 | Total company revenue |
| Revenue per Share | $9.057 | Total revenue divided by shares outstanding |
| Gross Profit | 54.73% | Revenue minus cost of goods sold |
| Return on Assets | 0.98% | Net income / Total assets |
| Return on Equity | 6.83% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 4.80% | Year-over-year revenue growth |
| Gross Margin | 54.73% | Gross profit / Total revenue |
| EBITDA Margin | 18.78% | EBITDA / Revenue |
| Operating Margin | 6.85% | Operating income / Revenue |
| Profit Margin | 9.68% | Net income / Revenue |
| Free Cash Flow | $1,212,375,040 | Cash left after capital expenditures |
| Operating Cash Flow | $572,000,000 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |